Ekso Bionics reported FY 2025 revenue of USD 12.8 million (-29%), with gross profit of USD 6.85 million (-28%) and gross margin of 53%. The company posted a FY 2025 operating loss of USD 13.33 million (+27%) and a net loss of USD 11.7 million (+3%). Net cash used in operating activities was USD 11.8 million in FY 2025, and cash and restricted cash ended the year at USD 1.17 million. Ekso Bionics said the FY 2025 revenue decline was primarily driven by lower Enterprise Health device sales volume in EMEA, partially offset by higher Personal Health device sales volume in the Americas. The company highlighted continued progress in its Personal Health go-to-market efforts for the Ekso Indego Personal, noting that as of December 31, 2025 it had over 50 people it believes qualify for potential reimbursement, and that its channel partners saw an increased number of Medicare claims submitted and reimbursed during 2025. Ekso Bionics also said it began marketing the MediTouch BalanceTutor in late 2025 under an exclusive distribution agreement and expects to begin sales and distribution in early 2026, while Nomad was for sale in limited volumes for use in a non-company-sponsored single clinical study, with general commercialization expected to begin in late 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ekso Bionics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-005086), on February 23, 2026, and is solely responsible for the information contained therein.